The Zhitong Finance App learned that CITIC Lyon released a research report saying that Cansino Biotech (06185.HK)'s revenue and net profit for the second quarter were in line with expectations, but the target price was lowered from HK$53.2 to HK$49.6, reflecting the higher R&D costs of its pipeline and maintaining a “outperforming the market” rating.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.